Background
H.R. 4818 was introduced on July 20, 2023, and was referred
to the Committee on Ways and Means and the Committee on Energy
and Commerce.
Committee Hearings
The Committee on Ways and Means held the following
hearing(s) concerning the policy in H.R. 4818:
On May 10, 2023, the Committee on Ways and Means Health
Subcommittee held a hearing titled, Examining Policies that
Inhibit Innovation and Patient Access to probe policies
limiting the number of innovative treatments and cures that
reach patients. The hearing explored Medicare's prohibition of
Part D plans covering anti-obesity medications.
Committee Action
The Committee on Ways and Means marked up H.R. 4818, the
Treat and Reduce Obesity Act of 2023, on June 27, 2024, and
favorably reported the bill, as amended, to the House of
Representatives (with quorum being present).
D. Designated Hearing
Pursuant to clause 3(c)(6) of rule XIII, the following
hearing was used to develop and consider H.R. 4818:
``Examining Policies that Inhibit Innovation and Patient
Access.'' May 10, 2023
II. EXPLANATION OF THE BILL
A. Reasons for Change
The Committee on Ways and Means' reason for change is to
update Medicare Part D policy to ensure seniors aging into
Medicare can continue treatment on anti-obesity medications
they have taken previously. Additionally, the committee wants
to ensure Medicare's coverage of intensive behavioral therapy
reflects current guidelines for the treatment of obesity.
B. Explanation of Provisions
Section 1. Short Title
The short title is ``Treat and Reduce Obesity Act of
2024''.
Section 2. Including Weight Loss Agents as Covered Part D Drugs Under
the Medicare Program in Certain Circumstances
Provides Medicare Part D coverage of anti-obesity
medications (AOMs) to individuals aging into Medicare who are
currently being treated by an AOM, ensuring they do not lose
coverage for their effective therapies.
Section 3. Reviewing Coverage for Intensive Behavioral Therapy for
Obesity Under the Medicare Program
Requires Medicare to re-evaluate its coverage of Intensive
Behavioral Therapy (IBT) so that seniors can be effectively
treated through diet and exercise.
C. Effective Date
The bill would become effective January 1, 2027.
III. VOTES OF THE COMMITTEE
In compliance with the Rules of the House of
Representatives, the following statement is made concerning the
vote of the Committee on Ways and Means during the markup
consideration of H.R. 4818, the ``Treat and Reduce Obesity Act
of 2023,'' on June 27, 2024.
The vote on the amendment offered by Mr. Doggett to the
amendment in the nature of a substitute to H.R. 4818, which
would require CMS to negotiate the price of drugs receiving
Medicare coverage under this legislation was not agreed to by a
roll call vote of 17 yeas to 23 nays (with a quorum being
present). The vote was as follows:
----------------------------------------------------------------------------------------------------------------
Representative Yea Nay Present Representative Yea Nay Present
----------------------------------------------------------------------------------------------------------------
Mr. Smith (MO)..................... ...... X ......... Mr. Neal............. X ...... .........
Mr. Buchanan....................... ...... X ......... Mr. Doggett.......... X ...... .........
Mr. Smith (NE)..................... ...... X ......... Mr. Thompson......... X ...... .........
Mr. Kelly.......................... ...... X ......... Mr. Larson........... X ...... .........
Mr. Schweikert..................... ...... X ......... Mr. Blumenauer....... X ...... .........
Mr. LaHood......................... ...... X ......... Mr. Pascrell......... X ...... .........
Dr. Wenstrup....................... ...... X ......... Mr. Davis............ X ...... .........
Mr. Arrington...................... ...... ...... ......... Ms. Sanchez.......... X ...... .........
Dr. Ferguson....................... ...... X ......... Ms. Sewell........... X ...... .........
Mr. Estes.......................... ...... X ......... Ms. DelBene.......... X ...... .........
Mr. Smucker........................ ...... X ......... Ms. Chu.............. X ...... .........
Mr. Hern........................... ...... X ......... Ms. Moore............ X ...... .........
Ms. Miller......................... ...... X ......... Mr. Kildee........... X ...... .........
Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... .........
Mr. Kustoff........................ ...... X ......... Mr. Evans............ ...... ...... .........
Mr. Fitzpatrick.................... ...... X ......... Mr. Schneider........ X ...... .........
Mr. Steube......................... ...... ...... ......... Mr. Panetta.......... X ...... .........
Ms. Tenney......................... ...... X ......... Mr. Gomez............ X ...... .........
Mrs. Fischbach..................... ...... X .........
Mr. Moore.......................... ...... X .........
Mrs. Steel......................... ...... X .........
Ms. Van Duyne...................... ...... X .........
Mr. Feenstra....................... ...... X .........
Ms. Malliotakis.................... ...... X .........
Mr. Carey.......................... ...... X .........
----------------------------------------------------------------------------------------------------------------
In compliance with the Rules of the House of
Representatives, the following statement is made concerning the
vote of the Committee on Ways and Means during the markup
consideration of H.R. 4818, the ``Treat and Reduce Obesity Act
of 2023,'' on June 27, 2024.
The vote on the amendment offered by Mr. Schneider to the
amendment in the nature of a substitute to H.R. 4818, which
would remove restrictions on Part D coverage of anti-obesity
medications, returning Part D coverage for anti-obesity
medications back to the original coverage provided in H.R. 4818
was not agreed to by a roll call vote of 15 yeas to 22 nays to
1 present (with a quorum being present). The vote was as
follows:
----------------------------------------------------------------------------------------------------------------
Representative Yea Nay Present Representative Yea Nay Present
----------------------------------------------------------------------------------------------------------------
Mr. Smith (MO)..................... ...... X ......... Mr. Neal............. X ...... .........
Mr. Buchanan....................... ...... X ......... Mr. Doggett.......... ...... ...... X
Mr. Smith (NE)..................... ...... X ......... Mr. Thompson......... X ...... .........
Mr. Kelly.......................... ...... X ......... Mr. Larson........... X ...... .........
Mr. Schweikert..................... ...... X ......... Mr. Blumenauer....... X ...... .........
Mr. LaHood......................... ...... X ......... Mr. Pascrell......... X ...... .........
Dr. Wenstrup....................... ...... X ......... Mr. Davis............ X ...... .........
Mr. Arrington...................... ...... ...... ......... Ms. Sanchez.......... X ...... .........
Dr. Ferguson....................... ...... X ......... Ms. Sewell........... X ...... .........
Mr. Estes.......................... ...... X ......... Ms. DelBene.......... X ...... .........
Mr. Smucker........................ ...... X ......... Ms. Chu.............. X ...... .........
Mr. Hern........................... ...... X ......... Ms. Moore............ X ...... .........
Ms. Miller......................... ...... X ......... Mr. Kildee........... X ...... .........
Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... .........
Mr. Kustoff........................ ...... X ......... Mr. Evans............ ...... ...... .........
Mr. Fitzpatrick.................... ...... X ......... Mr. Schneider........ X ...... .........
Mr. Steube......................... ...... ...... ......... Mr. Panetta.......... X ...... .........
Ms. Tenney......................... ...... X ......... Mr. Gomez............ X ...... .........
Mrs. Fischbach..................... ...... X .........
Mr. Moore.......................... ...... X .........
Mrs. Steel......................... ...... X .........
Ms. Van Duyne...................... ...... X .........
Mr. Feenstra....................... ...... X .........
Ms. Malliotakis.................... ...... X .........
Mr. Carey.......................... ...... X .........
----------------------------------------------------------------------------------------------------------------
In compliance with the Rules of the House of
Representatives, the following statement is made concerning the
vote of the Committee on Ways and Means during the markup
consideration of H.R. 4818, the ``Treat and Reduce Obesity Act
of 2023,'' on June 27, 2024.
The vote on the amendment offered by Mr. Beyer to the
amendment in the nature of a substitute to H.R. 4818, which
would add a study on impacts of GLP-1s on gut health was not
agreed to by a roll call vote of 17 yeas to 21 nays (with a
quorum being present). The vote was as follows:
----------------------------------------------------------------------------------------------------------------
Representative Yea Nay Present Representative Yea Nay Present
----------------------------------------------------------------------------------------------------------------
Mr. Smith (MO)..................... ...... X ......... Mr. Neal............. X ...... .........
Mr. Buchanan....................... ...... X ......... Mr. Doggett.......... X ...... .........
Mr. Smith (NE)..................... ...... X ......... Mr. Thompson......... X ...... .........
Mr. Kelly.......................... ...... X ......... Mr. Larson........... X ...... .........
Mr. Schweikert..................... ...... X ......... Mr. Blumenauer....... X ...... .........
Mr. LaHood......................... ...... X ......... Mr. Pascrell......... X ...... .........
Dr. Wenstrup....................... ...... X ......... Mr. Davis............ X ...... .........
Mr. Arrington...................... ...... ...... ......... Ms. Sanchez.......... X ...... .........
Dr. Ferguson....................... ...... X ......... Ms. Sewell........... X ...... .........
Mr. Estes.......................... ...... X ......... Ms. DelBene.......... X ...... .........
Mr. Smucker........................ ...... X ......... Ms. Chu.............. X ...... .........
Mr. Hern........................... ...... X ......... Ms. Moore............ X ...... .........
Ms. Miller......................... ...... ...... ......... Mr. Kildee........... X ...... .........
Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... .........
Mr. Kustoff........................ ...... X ......... Mr. Evans............ ...... ...... .........
Mr. Fitzpatrick.................... ...... X ......... Mr. Schneider........ X ...... .........
Mr. Steube......................... ...... ...... ......... Mr. Panetta......... X ...... .........
Ms. Tenney......................... ...... X ......... Mr. Gomez............ X ...... .........
Mrs. Fischbach..................... ...... X ......... ..................... ...... ...... .........
Mr. Moore.......................... ...... X ......... ..................... ...... ...... .........
Mrs. Steel......................... ...... X ......... ..................... ...... ...... .........
Ms. Van Duyne...................... ...... X ......... ..................... ...... ...... .........
Mr. Feenstra....................... ...... X ......... ..................... ...... ...... .........
Ms. Malliotakis.................... ...... X ......... ..................... ...... ...... .........
Mr. Carey.......................... ...... X ......... ..................... ...... ...... .........
----------------------------------------------------------------------------------------------------------------
In compliance with the Rules of the House of
Representatives, the following statement is made concerning the
vote of the Committee on Ways and Means during the markup
consideration of H.R. 4818, the ``Treat and Reduce Obesity Act
of 2023,'' on June 27, 2024.
H.R. 4818 was ordered favorably reported to the House of
Representatives as amended by a roll call vote of 36 yeas to 4
nays (with a quorum being present). The vote was as follows:
----------------------------------------------------------------------------------------------------------------
Representative Yea Nay Present Representative Yea Nay Present
----------------------------------------------------------------------------------------------------------------
Mr. Smith (MO)..................... X ...... ......... Mr. Neal............. ...... X .........
Mr. Buchanan....................... X ...... ......... Mr. Doggett.......... ...... X .........
Mr. Smith (NE)..................... X ...... ......... Mr. Thompson......... X ...... .........
Mr. Kelly.......................... X ...... ......... Mr. Larson........... X ...... .........
Mr. Schweikert..................... X ...... ......... Mr. Blumenauer....... X ...... .........
Mr. LaHood......................... X ...... ......... Mr. Pascrell......... X ...... .........
Dr. Wenstrup....................... X ...... ......... Mr. Davis............ X ...... .........
Mr. Arrington...................... X ...... ......... Ms. Sanchez.......... ...... X .........
Dr. Ferguson....................... X ...... ......... Ms. Sewell........... X ...... .........
Mr. Estes.......................... X ...... ......... Ms. DelBene.......... X ...... .........
Mr. Smucker........................ X ...... ......... Ms. Chu.............. X ...... .........
Mr. Hern........................... X ...... ......... Ms. Moore............ X ...... .........
Ms. Miller......................... X ...... ......... Mr. Kildee........... X ...... .........
Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... .........
Mr. Kustoff........................ X ...... ......... Mr. Evans............ ...... ...... .........
Mr. Fitzpatrick.................... X ...... ......... Mr. Schneider........ ...... X .........
Mr. Steube......................... ...... ...... ......... Mr. Panetta......... X ...... .........
Ms. Tenney......................... X ...... ......... Mr. Gomez............ X ...... .........
Mrs. Fischbach..................... X ...... ......... ..................... ...... ...... .........
Mr. Moore.......................... X ...... ......... ..................... ...... ...... .........
Mrs. Steel......................... X ...... ......... ..................... ...... ...... .........
Ms. Van Duyne...................... X ...... ......... ..................... ...... ...... .........
Mr. Feenstra....................... X ...... ......... ..................... ...... ...... .........
Ms. Malliotakis.................... X ...... ......... ..................... ...... ...... .........
Mr. Carey.......................... X ...... ......... ..................... ...... ...... .........
----------------------------------------------------------------------------------------------------------------
IV. BUDGET EFFECTS OF THE BILL
A. Committee Estimate of Budgetary Effects
With respect to clause 3(d) of rule XIII of the Rules of
the House of Representatives, a cost estimate provided by the
Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not made available to the
Committee in time for the filing of this report.
B. Statement Regarding New Budget Authority and Tax Expenditures Budget
Authority
In compliance with clause 3(c)(2) of rule XIII of the
Rules of the House of Representatives, the Committee states
that the bill involved no new or increased budget authority.
The Committee states further that the bill involves no new or
increased tax expenditures.
C. Cost Estimate Prepared by the Congressional Budget Office
With respect to the requirements of clause 3(c)(2) of rule
XIII of the Rules of the House of Representatives and section
308(a) of the Congressional Budget Act of 1974 and with respect
to requirements of clause (3)(c)(3) of rule XIII of the Rules
of the House of Representatives and section 402 of the
Congressional Budget Act of 1974, the Committee has requested
but not received a cost estimate for this bill from the
Director of Congressional Budget Office. The Chairman of the
Committee shall cause such estimate and statement to be printed
in the Congressional Record upon its receipt by the Committee.
V. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE
A. Committee Oversight Findings and Recommendations
With respect to clause 3(c)(1) of rule XIII of the Rules of
the House of Representatives, the Committee made findings and
recommendations that are reflected in this report.
B. Statement of General Performance Goals and Objectives
With respect to clause 3(c)(4) of rule XIII of the Rules of
the House of Representatives, the Committee advises that the
bill does not authority funding, so no statement of general
performance goals and objectives is required.
C. Information Relating to Unfunded Mandates
This information is provided in accordance with section 423
of the Unfunded Mandates Reform Act of 1995 (Pub. L. No. 104-
4).
The Committee has determined that the bill does not contain
Federal mandates on the private sector. The Committee has
determined that the bill does not impose a Federal
intergovernmental mandate on State, local, or tribal
governments.
D. Congressional Earmarks, Limited Tax Benefits, and Limited Tariff
Benefits
With respect to clause 9 of rule XXI of the Rules of the
House of Representatives, the Committee has carefully reviewed
the provisions of the bill, and states that the provisions of
the bill do not contain any congressional earmarks, limited tax
benefits, or limited tariff benefits within the meaning of the
rule.
E. Duplication of Federal Programs
In compliance with clause 3(c)(5) of rule XIII of the Rules
of the House of Representatives, the Committee states that no
provision of the bill establishes or reauthorizes: (1) a
program of the Federal Government known to be duplicative of
another Federal program; (2) a program included in any report